(R)-3-(1-Aminoethyl)-4-fluorobenzonitrile, 98%, 1g

(4S,5R)-4,5-DIPHENYL-2-(PYRIDIN-2-YL)-4,5-DIHYDROOXAZOLE, 95%, 100mg

(S)-3-(4-Bromophenyl)-3-((tert-butoxycarbonyl)amino)propanoic acid, 95.0%, 100mg

Colonne capillaire GC ROTI®Cap-5, 15 m, 0,32 mm, 0,10 µm, 1 pièce(s)

Ethyl 3-(hydroxymethyl)-1-methyl-1H-pyrazole-5-carboxylate, 95.0%, 1g

Hafnocene Dichloride>98.0%(T)5g

(S)-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)PYRROLIDINE, 97.0%, 25g

N-Benzyl-N-methylprop-2-yn-1-amine, 95.0%, 25g

3,4-Dichlorobenzyl Bromide>98.0%(GC)5g

Methyl 2-bromo-6-methoxynicotinate, 95.0%, 5g

(5aR,10bS)-2-(2,4,6-Triisopropylphenyl)-4,5a,6,10b-tetrahydroindeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate, 5g

(3R,4S)-4-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid, 97%, 100mg

(S)-1,3-Dihydrospiro[indene-2,4'-piperidin]-1-amine dihydrochloride, 97%, 1g